This content is in French.
Radium-223: a winning duo with enzalutamide?
25 novembre 2025
By Ana Espino | Published on November 25, 2025 | 2 min readMetastatic castration-resistant prostate cancer (mCRPC) represents an advanced and aggressive stage of the disease in which tumor cells continue to progress despite androgen suppression. It is characterized in most cases by bone metastases, which are responsible for considerable morbidity and increased mortality. These bone lesions expose
Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced and aggressive stage of the disease in which tumor cells continue to progress despite androgen suppression. It is characterized in most cases by bone metastases, which are responsible for considerable morbidity and increased mortality. These bone lesions expose patients to debilitating pain, pathological fractures, and serious complications such as spinal cord compression.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Tombal, B., et al. (2025). Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 36(9), 1058–1067
View the source
